Drug intelligence / Profile preview

SI-02

Development stage: Preclinical
Lead developer: SpikImm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

SI-02 is a monoclonal neutralizing antibody developed by SpikImm, a biotechnology company and spin-off from the Institut Pasteur. The antibody is designed to target the spike protein of the SARS-CoV-2 virus, thereby preventing the virus from entering and infecting host cells. SI-02 is being developed for the prevention and treatment of COVID-19, with a particular focus on providing protection to immunocompromised patients who may not achieve sufficient immunity through vaccination. As of the latest pipeline information, the drug is in the preclinical stage of development.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SI-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SI-02.

Explore the full profile